These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 2857148)
1. Recent developments in the treatment of Parkinson's disease. Greer M Geriatrics; 1985 Feb; 40(2):34-8, 41. PubMed ID: 2857148 [TBL] [Abstract][Full Text] [Related]
2. How to achieve maximum benefit for the patient with Parkinson's disease. Greer M Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356 [No Abstract] [Full Text] [Related]
3. The drug treatment of Parkinson's disease. Morris JG Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
6. Update on drug treatment of Parkinsonism. Winkelman AC Am Fam Physician; 1977 Jul; 16(1):118-20. PubMed ID: 18001 [No Abstract] [Full Text] [Related]
10. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Libman I; Gawel MJ; Riopelle RJ; Bouchard S Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120 [TBL] [Abstract][Full Text] [Related]
11. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias. Mark MH; Sage JI Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565 [TBL] [Abstract][Full Text] [Related]
12. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related]
14. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
17. Update on the treatment of Parkinson's disease. Wirz D Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903 [No Abstract] [Full Text] [Related]
18. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479 [TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease: new treatments. Stewart RM Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986 [TBL] [Abstract][Full Text] [Related]
20. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Pearce RK; Banerji T; Jenner P; Marsden CD Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]